Human papillomavirus (HPV) infection in Southern Africa: Prevalence, immunity, and vaccine prospects

IUBMB Life

Volumn 53, Issue 4-5, 2002, Pages 253-258

  Williamson, Anna Lise ^a   Marais, Dianne ^a   Passmore, Jo Ann ^a   Rybicki, Ed ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Cervical cancer; Human papillomavirus (HPV); Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; LIVE VACCINE; PLASMID DNA; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE; IMMUNOGLOBULIN A;

AFRICA; ANIMAL MODEL; CANCER RISK; CANCER SCREENING; CELLULAR IMMUNITY; CHIMERA; COMORBIDITY; CONFERENCE PAPER; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; NONHUMAN; PREVALENCE; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; VIRUS TYPING; WART VIRUS; ANIMAL; BLOOD; IMMUNOLOGY; MASS SCREENING; REVIEW; SOUTH AFRICA;

ANIMAL; FEMALE; HIV INFECTIONS; HUMAN; IMMUNOGLOBULIN A; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; SOUTH AFRICA; VACCINES, DNA; ANIMALS; HUMANS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; RNA VIRUSES;

EID: 0035991708     PISSN: 15216543     EISSN: None     Source Type: Journal    
DOI: 10.1080/15216540212654     Document Type: Conference Paper

References (84)

1. National Institutes of Health Consensus Development Conference statement on cervical cancer
2. HPV is a necessary cause of invasive cervical cancer worldwide
3. Prevalence of human papillomavirus in cervical cancer: A world wide perspective
4. Typing of human papillomaviruses in cervical carcinoma biopsies from Cape Town
5. Population based study of HPV infection and cervical neoplasia in rural Costa Rica
6. Th1 cytokine patterns in cervical human papillomavirus infection
7. Cell-mediated immunity to papillomaviruses
8. Immune responses against HPV type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16
9. Cervical mucus antibodies against HPV type 16, 18, and 33 capsids in relation to presence of viral DNA
10. Detection of cervical antibodies to HPV-16 capsid antigen in relation to detection of HPV-16 DNA and cervical lesions
11. Oral antibodies to HPV type 16 in women with cervical neoplasia
12. Papillomaviruses: Prophylactic vaccine prospects
13. Serum IgG, IgM and IgA reactivity HPV types 11 and 6 virus-like particles in different gynaecologic groups
14. The natural history of HPV type 16 capsid antibodies among a cohort of university women
15. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection
16. Serologically diagnosed infection with HPV type 16 and risk for subsequent development of cervical carcinoma: Nested case-control study
17. Serological responses to HPV-16 virus-like particles in HPV-16 DNA-positive invasive cancer and cervical intraepithelial neoplasia grade III patients and controls from Columbia and Spain
18. Age distribution of antibodies to HPV in children, women with cervical intraepithelial neoplasia and blood donors from South Africa
19. Seroresponses to HPV types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia
20. Cellular immunity in cutaneous and genital HPV infections
21. HPV in the immuno-suppressed
22. Langerhans cells and lymphocyte subsets in the female genital tract
23. Normal uterine cervix: Characterization of isolated lymphocyte phenotypes and immunoglobulin secretion
24. Immuno-cytochemical characterisation of large granular lymphocytes in normal cervix and HPV associated disease
25. Immunobiology of papillomavirus infections
26. Regression of canine oral papillomas is associated with infiltration of CD4 and CD8 lymphocytes
27. Immunological events in regressing genital warts
28. DTH responses to the HPV type 16 E7 protein in a mouse model
29. DTH response to HPV type 16 E6 protein in a mouse model
30. Immunization with non-structural proteins E1 and E2 or CRPV stimulates regression of virus-induced papillomas
31. T cell responses to HPV in cervical dysplasia
32. Human T cell responses to HPV type 16 L1 and E6 synthetic peptides: Identification of T cell determinants, HLA-DR restriction and virus type specificity
33. Definition of immunogenic determinants of the HPV type 16 nucleoprotein E7
34. Proliferative T cell responses to HPV type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals
35. Human T helper cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of HPV type 16
36. T cell proliferative response to HPV type 16 peptides: Relationship to cervical intraepithelial neoplasia
37. Proliferative T cell responses to HPV type 16 E5 are decreased amongst women with high grade neoplasia
38. Isolation and characterization of HPV type 6-specific T cells infiltrating genital warts
39. HPV infection in women infected with HIV
40. The correlation between HIV seropositivity, cervical dysplasia and HPV sub-types 6/11, 16/18, 31/33/35
41. HIV infection in vitro activates naturally integrated human papillomavirus type 18 and induces synthesis of the LI capsid protein
42. The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription
43. HIV type 1 tat gene enhances human papillomavirus early gene expression
44. Postmodern cancer: The role of HIV in uterine cervical cancer
45. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour
46. Prevalence of anti-HPV type 16, 18, 31, and 58 virus-like particles in women in the general population and prostitutes
47. The impact of HIV type 1 status on HPV prevalence and HPV antibodies in serum and cervical secretions
48. Differences in serolgical IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia
49. Cervical abnormality and sexually transmitted disease screening in HIV-positive women
50. Papillomavirus-like particle based vaccines: Cervical cancer and beyond
51. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
52. The role of vaccines in the control of STDs: HPV vaccines
53. Papillomavirus capsid protein expression in Escherichia coli: Purification and assembly of HPV11 and HPV16 L1
54. Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of viruslike particles
55. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies
56. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers
57. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
58. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies
59. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA
60. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
61. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer
62. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes
63. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies
64. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins
65. Chimeric papillomavirus-like particles
66. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumor model
67. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
68. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6
69. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies
70. Protection against papillomavirus with a polynucleotide vaccine
71. Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge
72. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits
73. Induction of an HPV 6b L1-specific mucosal IgA response by DNA immunization
74. Enhancement of capsid gene expression: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes
75. In vitro gene transfer using HPV VLPs
76. Papillomavirus pseudovirus: A novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses